Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium lu 177 vipivotide tetraxetan
- Development stage
- Approved
- Lead developer
- Novartis
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
Lutetium lu 177 vipivotide tetraxetan is a radiopharmaceutical used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in adults who have previously been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. It consists of a PSMA-targeting ligand (PSMA-617) conjugated to the beta-emitting radioisotope lutetium-177 via a DOTA chelator. The drug binds to PSMA-expressing cells, delivering targeted radiation that induces DNA damage and cell death in both cancerous and surrounding cells. Lutetium lu 177 vipivotide tetraxetan was first approved in the United States on March 23, 2022, and is marketed under the brand name Pluvicto[1][3][5].
- Brand names
- Pluvicto
- Other names
- PSMA-617PSMA617PSMA 617lutetium-177 vipivotide tetraxetanlutetium177 vipivotide tetraxetanlutetium 177 vipivotide tetraxetan
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium lu 177 vipivotide tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium lu 177 vipivotide tetraxetan.